This study will be a 12 weeks, douled blind, placebo-controlled, parallel group study of YY-312 demonstrated to reduce body weight in the previous studies of obese Korean for the evaluation of the efficacy and safety of body weight and body fat mass loss. 

1. Primary endpoints 
- Change in body fat percent and body fat mass by DEXA compared placebo and YY-312 from baseline at 12 weeks. 
2. Secondary endpoints 
- Change in body weight and body waist compared placebo and YY-312 from baseline at 12 weeks

 Supportive Care

Subjects will be randomized to receive YY-312 1,800mg or placebo. Subjects will orally self-adminster YY-312 1,800mg or placebo, 3 capsules twice per day for 12 weeks.  

Arm Label

Target Number of Participant

Arm Type

Arm Description

Subjets will take orally self-administer YY-312 1,800mg, 3 capsules twice per day for 12weeks.  

Arm Label

Target Number of Participant

Arm Type

Arm Description

Subjets will take orally self-administer placebo, 3 capsules twice per day for 12weeks.  

Gender

Age

Description

1) Male and female subjects between 19-60years of age inclusive. 
2) BMI of 25.0 - 30.0kg/m2 
3) Evidense of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial

1) Subjects with systolicBP ≥ 160 mmHg or diastolicBP ≥ 100 mmHg and also taking a beta blocker or a hydragogue
2) Subjects with diabetes(use of hypoglycemic agent or insulin)or fasting blood glucose ≥ 126 mg/dL or random blood glucose ≥ 200 mg/dL
3) Subjects with endocrinopathy or abnormal screening TSH(Thyroid-Stimulating Hormone) value(≤0.1uU/ml or ≥10 uU/ml)
4) Subjects with  hyperlipidemia) (fasting triglycerides > 600mg/dl)
5) Serum AST(aminotransferse)/ALT(alanine amintransferse) ≥ 3 times the upper limit of normal
6) Serum creatinine ≥ 1.5 times the upper limit of normal 
7) Use of prescription drugs or supplements known to alter body weight or appetite, antidepressants, oral contraceptive, steroid, female sex hormon
8) Subjects with taking drugs that can affect the body weight within the 3 months
9) Subjects with clinically significant cardiovascular disease within the 6 months prior to screening
10) Subjects who change weight more than 4kg within 4 months 
11) Subjects with pancreatopathy 
12) Subjects with chronic malabsorption syndrome or bile secretion disorder
13) Subjects with undergoing gastrointestinal operation for reducing boy weight
14) Subjects with postoperative intestinal adhesion 
15) Subjects with a history of cancer and intervention within the 5 years prior to screening
16) Subjects with a history of CNS(central nervous system) disorder(depressive disorder, schizophrenia, alcoholism, drug addiction)
17) Subjects with heart disease, kidney disease, liver disease, lung disease and cerebrovascular disease
18) Subjects with gallbladder diseases, gastrointestinal diseases, gout and porphyria
19) Subjects with asthma and allergic disease 
20) Subjects with bulimia and abuse of relievers
21) Women of childbearing age who are disagreed with effective contraceptions in the clinical trial period
22) Woman who are pregnant or lactating 
23) Participation in any clinical trial within the 1 month prior to screening. 
24) Subjects who could affect preclude evaluation of response in the opinion investigator

Fat percentage(by DEXA)  

From baseline at 12 weeks  

Fat mass(by DEXA)  

From baseline at 12 weeks  

Body weight

From baseline at 12 weeks  

Waist circumference 

From baseline at 12 weeks